New Alliance for Regenerative Medicine (ARM) report documents a ‘year of firsts’ for the cell and gene therapy sector.
According to the new ARM report, which focuses on the first half of 2021, the regenerative medicine and advanced therapies sector has seen a best-ever six-month period of financing, raising $14.1B from January through June, reaching 71% of the record amount raised in the entirety of the previous year.
With four new regenerative medicine products having already gained regulatory approval this year, and decisions pending on six more, 2021 could also see the sector break the previous record of nine approvals seen back in 2016.
“The regenerative medicine sector is accelerating across all fronts simultaneously,” said Janet Lambert, CEO of ARM, in a press release. “Scientific progress is driving intense interest among investors. Companies are forming, maturing, and increasingly moving promising therapies toward approval. And we’re seeing rising global competition to cultivate this sector and deliver access for patients.”
More highlights from the ARM report include: